Ipsen and Saol partner to co-promote Dysport in US

The US affiliate of French pharmaceutical company Ipsen has entered an exclusive, three-year agreement with Saol Therapeutics to promote Dysport (abobotulinumtoxinA) for approved therapeutic indications in adult spasticity and pediatric lower limb sp …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news